Mochi Health Review: Questions to Settle Before You Enroll

01Start with the first charge—and the next one

Mochi’s membership display offers $199 for the first 12 months, due today, alongside a rounded $17-per-month equivalent and an advertised $39 saving. For decision-making, the immediate transaction matters more than the equivalent: this offer collects $199 upfront. A separate banner advertises $79 off membership and the first month free specifically on a one-month plan. That promotion is about membership, not free medication. The consulted pages do not establish the subsequent charges for every plan or explain whether these offers can be combined.

Ask Mochi to identify the exact plan attached to your checkout, the amount charged now, the next billing date and the amount due then. Also request an explanation of what happens financially if the clinician does not prescribe medication. The annual offer establishes a prepaid membership period; it does not establish a medication supply or, by itself, settle cancellation consequences. A useful comparison starts with actual cash due rather than converting every offer into a monthly number.

The site promises no hidden fees and cancellation at any time, but those statements do not answer whether unused prepaid membership is refundable. The refund policy itself was not available in the consulted documentation. Before paying, request the cancellation method, the deadline for preventing another charge and the treatment of an unused annual balance. Our questions to settle before the next charge can help turn a broad cancellation promise into specific written answers.

02Identify the clinical practice behind your appointment

Mochi distinguishes its corporate role from the delivery of medical care. Mochi Health Corp. says it supplies administrative and technology services and does not itself provide professional medical services. Licensed physicians and other clinicians affiliated with independently owned and operated practices provide that care. This distinction matters when asking who evaluates your history, writes a prescription, maintains the clinical relationship or addresses a medical concern. The consulted pages do not identify the particular professional practice that would serve an individual patient.

The homepage invites patients to choose a medical provider it describes as board certified and a registered dietitian. The tirzepatide page describes a live, 30-minute video appointment with a doctor. Those statements describe the advertised team and appointment format, not independent verification of credentials or a guarantee that every interaction is with a physician. Ask for the treating professional’s name, credential, practice affiliation and role, along with whether you can keep the same professional for follow-up.

The documented intake begins with a short health-history questionnaire, and Mochi says laboratory testing may be ordered when needed. Thirty minutes describes the video visit’s length, not how soon it can be scheduled. Before purchasing, clarify when clinical review occurs, whether payment precedes that review and what happens if additional records or tests are necessary. The pages do not provide appointment-wait guarantees or a complete description of how an unsuccessful intake affects charges.

03Ask for the exact medicine, not simply a GLP-1 option

Mochi advertises compounded, once-weekly subcutaneous tirzepatide starting at $90 plus membership and compounded, once-weekly subcutaneous semaglutide starting at $60 plus membership. Both are offered at the prescriber’s discretion, require a written prescription and have dose-dependent pricing. Neither quoted price block identifies the supply period. Do not assume those amounts buy a calendar month or four weeks. Ask for the exact formulation, presentation, quantity, supply period and total medication charge in the offer you would actually receive.

The oral semaglutide page advertises a compounded, once-weekly pill starting at $62 per month plus membership, also at prescriber discretion. That is a different route and advertised schedule from the injectable offers, not merely another price for the same presentation. The homepage also lists compounded oral orforglipron. These descriptions are provider claims about its catalog, not individualized instructions or independent confirmation of the preparations’ performance. Our guide to identifying the medicine behind an offer explains why formulation and route belong in any comparison.

The branded catalog includes injectable Zepbound and Wegovy, Foundayo, Wegovy Pill, Mounjaro and Ozempic; metformin is also listed. Mochi describes Mounjaro for type 2 diabetes and Ozempic for type 2 diabetes with additional benefits in eligible adults, rather than presenting every product as having the same indication. Its product-specific approval claims should not be read as FDA approval of Mochi or its compounded preparations. Catalog presence also does not establish that a particular patient, state or insurance plan can access each option.

04Separate insurance help from insurance coverage

Mochi says it handles prior authorization when medication is prescribed and coordinates delivery or local pickup. It also advertises cash-pay and compounded options for people without insurance. These are distinct access routes, not evidence that insurance will cover a prescription. In its insurance-care block, the site says visits are billed through insurance and the copay is shown before commitment. Ask which route your enrollment uses, which practice bills the visit and whether a quoted membership amount applies alongside any insurance-billed services.

Membership explicitly excludes medications and diagnostic services. Consequently, laboratory tests may be part of the care process without being included in the subscription price. Ask where tests would be performed, who bills for them and whether an estimated patient charge is available before testing. Similarly, ask what happens if prior authorization is denied or delayed: whether there is an appeal process, what alternatives may be discussed and whether membership charges continue during the wait. The consulted pages do not settle those operational details.

NIDDK notes that some plans cover weight-management medication and others do not. Consultation coverage and medication coverage therefore need separate confirmation with the plan. Mochi’s authorization support may help with paperwork, but the public documentation does not establish approval rates or guarantee coverage. A practical request is an itemized explanation separating membership, visit copays, medication and diagnostics. That makes it easier to identify what the provider can quote and what still requires an answer from the insurer.

05Determine what ongoing access actually means

Mochi advertises unlimited visits with the care team as part of membership. Its homepage also describes provider video visits as often as needed, ongoing nutrition and wellness guidance, and follow-up laboratory testing. This is a broader advertised service than prescription fulfillment alone. Nevertheless, unlimited access does not resolve the billing distinction on the insurance pathway: visits may be billed to insurance with copays. Ask which visits are included under your specific arrangement, who provides them and whether any encounter generates an additional patient charge.

The site advertises care-team support around the clock, including help with insurance and prior authorization. It does not document a response-time promise in the consulted material. Availability of a support channel is not the same as immediate access to the prescribing clinician. Ask how to reach the clinical team between appointments, how routine messages differ from time-sensitive concerns and who covers when your usual professional is unavailable. Also confirm whether nutrition appointments must be separately scheduled and how continuity is handled.

Follow-up should be understood as a clinical service rather than merely another billing cycle. NIDDK describes medication decisions as involving response, side effects, other health conditions and costs, with nutrition and physical activity remaining part of care. For Mochi, the useful question is how those topics appear in actual follow-up: what is reviewed, when appointments are arranged and who explains any new testing. The documentation supports an ongoing-care offering, but it does not provide a detailed individual follow-up calendar.

06Find out which pharmacy is responsible for your order

Mochi describes purchasing medication through a pharmacy network and advertises prescription fulfillment with home delivery. Its homepage also mentions local pickup. The consulted excerpts do not name the network members, identify who compounds each preparation or establish which delivery and pickup options apply to each medication. Dispensing and compounding are different responsibilities. Ask for the dispensing pharmacy’s identity and contact information and, for a compounded preparation, which pharmacy makes it. Also ask whether the offered price depends on using a particular network channel.

The promise of reliable shipping is not a documented dispatch or arrival deadline. The pages do not establish clinical-review time, pharmacy processing time, transit time or replacement arrangements. Before ordering, ask when the order becomes eligible for fulfillment, how tracking is provided and who handles a missing, damaged or temperature-concerning package. Our delivery questions guide can help distinguish the pharmacy’s responsibilities from the program’s. The answer should identify a workable contact path, not just repeat that delivery is available.

FDA advises not using an injectable GLP-1 drug that arrives warm or with insufficient refrigeration and contacting the provider or dispensing pharmacy to resolve the concern. That guidance is general, not evidence of a shipping problem at Mochi. For this provider, the unanswered practical questions concern temperature-handling instructions, whom to contact after hours and whether replacement costs apply. The consulted documentation does not establish a cold-chain protocol or a specific reshipment promise.

07Bring eligibility and state-specific questions to intake

Mochi states that medication availability and pricing vary by state. Its public pages do not establish every treatment’s availability in every location, and a geographic selector would not by itself prove universal clinical coverage. Before choosing a payment plan, confirm that the clinical practice can serve you where you will receive care and that the specific medication pathway is available there. Ask whether a move or extended travel would affect appointments, prescribing or pharmacy fulfillment rather than assuming the same arrangement follows you everywhere.

The consulted pages do not establish a minimum age, complete eligibility criteria, contraindication screening or all circumstances that could prevent prescribing. That absence is not proof that screening does not occur. It means a prospective patient should request the provider’s actual criteria and explain their history during clinical intake. NIDDK advises discussing medicines, supplements, allergies and pregnancy plans with the treating clinician. A review cannot turn general eligibility concepts into a personal determination or predict what a Mochi professional will prescribe.

Communication access is another issue to settle before prepaying. The documentation does not confirm Spanish-language clinical care, interpretation services or clinical materials in Spanish. It also does not describe every contact channel a member receives after enrollment. Ask how appointment changes, clinical messages, billing disputes and pharmacy questions are routed, particularly if you need language assistance or a specific communication format. These are practical service-fit questions, not reasons to presume that an undocumented accommodation is either available or unavailable.

08Keep marketing claims separate from evidence

Mochi discloses that members featured in its testimonials were compensated for sharing their experiences. That transparency is useful, but the stories are not independent evidence of typical results. Nor do studies of a particular approved product establish outcomes for Mochi’s service, compounded preparations or different routes. When an advertisement makes a performance claim, ask what exact product and population support it and whether the figure describes this provider’s patients. The consulted documentation does not establish a provider-specific expected outcome for an individual.

Mochi also states that compounded medications are not FDA approved or evaluated by the agency for safety, effectiveness or quality. FDA’s guidance recommends compounded drugs when an individual’s medical needs cannot be met by an approved drug, with a prescription and a state-licensed pharmacy. Nonapproval alone does not establish clinical inequivalence, but neither does a familiar ingredient name establish equivalent evidence. The useful consultation question is why the proposed preparation addresses your medical needs and what approved alternatives were considered.

FDA has received reports of errors measuring or administering compounded GLP-1 medication, including some associated with hospitalization. These reports are not a Mochi-specific event rate. If a compounded product is proposed, ask who explains its instructions and whom you contact if the label or administration materials are unclear. Do not calculate a personal dose from a review. This is where the distinction between administrative support, the prescriber and the dispensing pharmacy becomes especially important: each should have an identifiable responsibility.

Questions & answers

Sources & documentation

Public materials consulted October 19, 2026. Provider statements are attributed claims, not independently verified clinical outcomes. Terms can change; obtain a current written quote.

1. FDA concerns with unapproved GLP-1 drugs used for weight loss ↗
2. NIDDK: prescription medications for overweight and obesity ↗
3. Wilding et al. (2021): STEP 1 semaglutide trial ↗
4. Jastreboff et al. (2022): SURMOUNT-1 tirzepatide trial ↗
5. Mochi Health — medications/compounded semaglutide ↗
6. Mochi Health — medications/compounded tirzepatide ↗
7. Mochi Health — official website ↗
8. Mochi Health — medications/compounded semaglutide pill ↗

Continue reading

• What Does a GLP-1 Program Need to Explain Before You Enroll?
• Ask What the Medicine Is Before Comparing the Offer
• Questions to Settle Before the Next GLP-1 Program Charge
• What to Ask About GLP-1 Shipping—and What to Do When a Delivery Goes Wrong
• GLP-1 Coverage Questions for Your Program and Your Health Plan